

Baxter International Inc.
Key Product Line Sales -- US/International
Period Ending March 31, 2004
(unaudited)

(\$ in millions)	Q1 2004			Q1 2003			% Growth		
	US	International	Total	US	International	Total	US	International	Total
BioScience									
Recombinants	\$ 141	\$ 151	\$ 292	\$ 119	\$ 125	\$ 244	18%	21%	19%
Plasma Proteins ¹	114	124	238	106	123	229	7%	1%	4%
Antibody Therapy	43	37	80	36	31	67	19%	19%	19%
Transfusion Therapies	65	75	140	63	71	134	4%	5%	4%
Other ²	22	38	60	16	50	66	38%	(24%)	(7%)
Total BioScience	\$ 385	\$ 425	\$ 810	\$ 340	\$ 400	\$ 740	13%	6%	9%
Medication Delivery									
IV Therapies ³	\$ 103	\$ 179	\$ 282	\$ 100	\$ 148	\$ 248	3%	21%	14%
Drug Delivery	126	48	174	122	39	161	4%	21%	8%
Electronic Infusion Systems	125	48	173	128	38	166	(2%)	28%	5%
Anesthesia	171	20	191	167	14	181	2%	40%	5%
Other ⁴	9	100	109	3	91	94	200%	10%	15%
Total Medication Delivery ⁵	\$ 534	\$ 395	\$ 929	\$ 520	\$ 330	\$ 850	3%	20%	9%
Renal									
PD Therapy	\$ 63	\$ 282	\$ 345	\$ 62	\$ 239	\$ 301	2%	18%	15%
HD Therapy	34	87	121	33	70	103	3%	24%	17%
Other	3	1	4	1	2	3	200%	(50%)	66%
Total Renal	\$ 100	\$ 370	\$ 470	\$ 96	\$ 311	\$ 407	4%	19%	16%
TOTAL BAXTER	\$1,019	\$1,190	\$2,209	\$956	\$1,041	\$1,997	7%	14%	11%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, plasma-based biosurgery (Tisseel) and other plasma-based products.

² Principally includes vaccines and non-plasma-based biosurgery products (FloSeal and CoSeal).

³ Principally includes intravenous solutions and nutritional products.

⁴ Principally includes oncology and other hospital-distributed products.

⁵ Sales of pain management products, which were previously included in Anesthesia, are now reported in either Electronic Infusion Systems or Other, depending on the product. All prior sales data has been reclassified to reflect this change.